Milton L. Greenberg, Ph.D.
Dr. Greenberg is a co-founder and the President of Vivreon Biosciences, where his passion is to solve unmet needs in chronic diseases. Dr. Greenberg is also an Assistant Adjunct Professor at the University of California, Irvine. He holds a Ph.D. in Biomedical Sciences from the University of California, Irvine and a B.S. in Biochemistry from the University of Maryland.
Andrew C. Newman, Ph.D.
Dr. Newman is a co-founder and the Chief Operating Officer of Vivreon Biosciences. Dr. Newman leads research and partnership efforts, ensuring that Vivreon’s commercial value is realized. Dr. Newman holds a Ph.D. in Biological Sciences from the University of California, Irvine and a B.S. in Genetics from the University of Wisconsin, Madison.
Omed Muzaffery, M.B.A., M.S.
Mr. Muzaffery is a co-founder and the Chief Financial Officer of Vivreon Biosciences. Mr. Muzaffery holds an M.B.A. from the University of Southern California Marshall School of Business, an M.S. in Material Science and Engineering from the University of California, Irvine and a B.S. in Chemistry from the University of California, Santa Cruz.
John T. Ransom, Ph.D.
Dr. Ransom is a co-founder and the Chief Scientific Officer of Vivreon Biosciences, where he leads Vivreon's drug development programs. Dr. Ransom has previously served in CSO and VP positions at multiple biotechnology and pharmaceutical companies, including BioLegend, Advanced Molecular Design, Cytori Therapeutics, and Novasite Pharmaceuticals. He holds a Ph.D. in Physiology from the University of Texas Southwestern Medical Center at Dallas and a B.S. in Biology from the University of Delaware.
Oral Immune Therapeutics